REPLIGEN CORP Debt Securities, Available-for-sale, Current
REPLIGEN CORP (RGEN) had Debt Securities, Available-for-sale, Current of $203.67 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments › Debt Securities, Current
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-07-29
- 2026-06-30: Debt Securities, Available-for-sale, Current $203.67M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $201.88M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $201.61M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $203.67M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $201.88M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $201.61M 10-Q · filed 2026-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |